Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HYG Guys !!
BIOCORX BOOTH LOCATION AT ASMA EXHIBIT HAPPENING TODAY !! BICX IS REAL
BOOTH # 431
http://www.asam.org/docs/default-source/medsci/exhibit-hall-diagram.pdf?sfvrsn=0
EVERY SINGLE BUY TODAY IS A VERY SMART BUY ... GO BICX
Bigger BICX Exposure !!! 4-6-17
http://www.walb.com/story/35085032/omahas-igotsober-alcohol-opioid-recovery-center-announces-formal-opening
BOOOOOOMMMMMM !!!! MORE NEWS OUT TODAY :)
Omaha's igotsober Alcohol & Opioid Recovery Center Announces Formal Opening
Center to Offer New Medication-Assisted Treatment (MAT) with BioCorRx®
News provided by
igotsober Alcohol & Opioid Recovery Center ?
Apr 06, 2017, 08:30 ET
OMAHA, Neb., April 6, 2017 /PRNewswire/ -- igotsober Alcohol & Opioid Recovery Center today announced its formal opening. The center helps those in need throughout Omaha and the Central United States with an outpatient program offered at approximately half the cost of traditional inpatient programs. The center is conveniently located in the heart of the city at 4905 Dodge Street between N. Saddle Creek Road and N. Happy Hollow Boulevard.
There are now 23.5 million American adults addicted to drugs and/or alcohol, states the Substance Abuse and Mental Health Services Administration's (SAMHSA's) National Survey on Drug Use and Health. The new center, a trusted BioCorRx® provider, through its outpatient treatment program employs a multi-component approach and a broad recovery support structure. This includes detox assistance, the long-lasting BioCorRx® implant (using FDA-approved medicine Naltrexone which removes or largely eliminates not just the desire to use and drink, but also the associated "high"), intensive one-on-one counseling, 24/7 Sobriety Coaching, and up to 12 months of expert support led by certified Peer Recovery Support Specialists (PRSS).
The program integrates relapse prevention strategies to help patients quickly take action upon identifying emotional, mental, and physical warning signs. Family counseling sessions are also available to help loved ones better understand patterns that might unintentionally contribute to a patient's addictive behaviors. Robust programs such as this have been shown to deliver much higher success rates than conventional methods alone.
"We're thrilled to now offer Omaha and our surrounding communities what we believe to be the safest and most effective Medication-Assisted Treatment available anywhere," states Leo Allison, the center's founder. "A consultation is available now at no-cost for anyone serious about liberating themselves from the grips of drug or alcohol addiction once and for all."
For more information on the igotsober Alcohol & Opioid Recovery Center and its outpatient recovery program, call (402) 552-8890 or visit www.igotsober.com.
About the igotsober Alcohol & Opioid Recovery Center
Founded by Leo Allison, the igotsober Alcohol & Opioid Recovery Center provides a revolutionary and multi-phase outpatient treatment program fueled by Medication-Assisted Treatment (MAT), specifically the non-narcotic, 100% biodegradable implant from BioCorRx® that slowly releases the anti-craving medicine Naltrexone over a period of months. The program allows patients to integrate their therapy in real-time and in real-life thanks to a clear mind. The innovative BioCorRx® Recovery Program has provided a success rate far superior to that of conventional inpatient programs and at just one-half the cost.
Media Contact:
Leo Allison
153721@email4pr.com
4025528890
Download the E*TRADE Mobile app and seize Opportunity anywhere.Advertisement
BOOOOOOMMMMMM !!!! MORE NEWS OUT TODAY :)
Omaha's igotsober Alcohol & Opioid Recovery Center Announces Formal Opening
Center to Offer New Medication-Assisted Treatment (MAT) with BioCorRx®
News provided by
igotsober Alcohol & Opioid Recovery Center ?
Apr 06, 2017, 08:30 ET
OMAHA, Neb., April 6, 2017 /PRNewswire/ -- igotsober Alcohol & Opioid Recovery Center today announced its formal opening. The center helps those in need throughout Omaha and the Central United States with an outpatient program offered at approximately half the cost of traditional inpatient programs. The center is conveniently located in the heart of the city at 4905 Dodge Street between N. Saddle Creek Road and N. Happy Hollow Boulevard.
There are now 23.5 million American adults addicted to drugs and/or alcohol, states the Substance Abuse and Mental Health Services Administration's (SAMHSA's) National Survey on Drug Use and Health. The new center, a trusted BioCorRx® provider, through its outpatient treatment program employs a multi-component approach and a broad recovery support structure. This includes detox assistance, the long-lasting BioCorRx® implant (using FDA-approved medicine Naltrexone which removes or largely eliminates not just the desire to use and drink, but also the associated "high"), intensive one-on-one counseling, 24/7 Sobriety Coaching, and up to 12 months of expert support led by certified Peer Recovery Support Specialists (PRSS).
The program integrates relapse prevention strategies to help patients quickly take action upon identifying emotional, mental, and physical warning signs. Family counseling sessions are also available to help loved ones better understand patterns that might unintentionally contribute to a patient's addictive behaviors. Robust programs such as this have been shown to deliver much higher success rates than conventional methods alone.
"We're thrilled to now offer Omaha and our surrounding communities what we believe to be the safest and most effective Medication-Assisted Treatment available anywhere," states Leo Allison, the center's founder. "A consultation is available now at no-cost for anyone serious about liberating themselves from the grips of drug or alcohol addiction once and for all."
For more information on the igotsober Alcohol & Opioid Recovery Center and its outpatient recovery program, call (402) 552-8890 or visit www.igotsober.com.
About the igotsober Alcohol & Opioid Recovery Center
Founded by Leo Allison, the igotsober Alcohol & Opioid Recovery Center provides a revolutionary and multi-phase outpatient treatment program fueled by Medication-Assisted Treatment (MAT), specifically the non-narcotic, 100% biodegradable implant from BioCorRx® that slowly releases the anti-craving medicine Naltrexone over a period of months. The program allows patients to integrate their therapy in real-time and in real-life thanks to a clear mind. The innovative BioCorRx® Recovery Program has provided a success rate far superior to that of conventional inpatient programs and at just one-half the cost.
Media Contact:
Leo Allison
153721@email4pr.com
4025528890
10K will be out before the 15th , FDA updates will be more accurate and out in the same time frame ...
IMO !! today, tomorrow and early next week is the final days to load in the 0.20s & 0.30s !!
XLI Technologies, Inc. Announces ""Revenue This Month During the Current Installations of 200 Nano-Printed Lightsheet Fixtures in Theaters"" Which Began the Week of March 20, 2017
Apr 06, 2017 06:00:00 (ET)
XLI Technologies, Inc. Announces "Revenue This Month During the Current Installations of 200 Nano-Printed Lightsheet Fixtures in Theaters" Which Began the Week of March 20, 2017
LAS VEGAS, April 06, 2017 (GLOBE NEWSWIRE) -- XLI Technologies, Inc. (OTC PINK:XLIT) (the "Company" or "XLI") is proud to announce sales and revenue during the continuation of the Printed LightSheet Fixture installations.
Advertisers benefit at less than a fraction of the cost from the multi-million dollar advertising campaigns of movies. The Printed LightSheet Fixtures are the only "In Theater" advertising that guarantees an average awareness of 90% per location (auditorium). The average cost to advertise is only $5.00 per movie showing. A list of the theaters and monthly sales/revenue amounts will be provided after the install program is complete.
James Schramm, CEO of XLI Technologies, Inc., commented, "Our objective is to sell advertising space as we are installing the fixtures. We have opened a marketing web site (LightSheets.net) designed specifically for this program and is used to facilitate the sales for XLI Technologies, Inc. It is working great. We received our first sale today April 6, 2017 from a major company. We currently have a lot of interest in which we expect to turn into more sales and revenue. Our objective is to sell all 200 fixtures by the time they are all installed. We are still actively pursuing investment opportunities to buy-out all debt and to pay for all the objectives in which will bring the company to current reporting status. We will provide a list of all advertisers (sales) and monthly revenue amounts at the time all 200 fixtures are installed. If we receive the much needed investment soon, we would be able to add an additional 500 installations in which would position XLI Technologies, Inc. in a rapid revenue generating position. I am so pleased to confirm that this month, April 2017 is the first month and the beginning of monthly revenue reporting."
About XLI Technologies, Inc.
XLI Technologies, Inc., provides unique, versatile, durable, and eco-friendly Nanotechnology printed lighting products (Printed LightSheets) to select companies in the automotive, construction and exclusively the entertainment sector, including movie theaters, movie studios, production and distribution companies, talent and management agencies, marketing and PR firms, and outdoor media in the USA and Canada. The Company is also exploring several other potential applications of the technology.
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with intellectual property protection, marketing and sale, manufacturing and distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
contact: Info@XLItech.com
(MORE TO FOLLOW) Dow Jones Newswires
April 06, 2017 06:00 ET (10:00 GMT)
Close @ .23
Alpine Creek completes equity financing of Biotech BioCorRx
Monday, April 03, 2017
California-based private investment firm Alpine Creek Capital has completed its equity financing of BioCorRx Inc. (BICX), an addiction treatment company offering a unique approach to the treatment of substance abuse addiction.
The new round of funding will include the closing of nearly $5m investment from strategic investor Alpine Creek Capital. Their initial investment of $2,500,000 received in June 2016 has allowed BioCorRx to reach major milestones and expand into the development of injectable naltrexone.
Lourdes Felix, CFO, COO and Director, stated, "We appreciate the support we have received from investors, as this financing strengthens our balance sheet while allowing us to continue to execute on our business plan. Preclinical studies of BICX101, a new injectable naltrexone technology for the treatment of substance abuse addiction, have produced results consistent with our goals. This funding will allow us to accelerate our preclinical activities, and we remain on track to complete the current study already underway in the following weeks. Once the study is completed, we plan to request a pre-IND meeting with the FDA to present the data. In addition, this financing will allow us to accelerate sales and marketing activities related to our BioCorRX Recovery Program."
that thing is ready to explode !! any second Now
Drug Addiction Treatment Should Start in Emergency Room
By Komfie Manalo
Apr 5, 2017
Drug addiction treatment should start in the emergency room because it can offer addicts timely access to treatment when they finally decide that they want it, said Brady Granier, President, CEO and Director of BioCorRx, Inc. (OTCQB:BICX).
Appearing as a guest on Fox Business Network's "Mornings with Maria", Granier explained that drug addiction is not like any disease where people tend to seek care and do anything to get treatment. It's unlike people with cancer who will typically do anything within their power to get treatment, he said.
"When an addict is ready for treatment but if they can't get access, as in right now, you'll lose them," Granier told Mornings with Maria anchor Maria Bartiromo and other guests participating in a roundtable discussion to emphasize the need to begin drug addiction treatment in the ER. "In drug addiction, you have windows of opportunities sometimes. And if you (addict) can't get immediate treatment, that's a problem. And then you'll lose them. I've seen that happen many times."
Opioid Epidemic
America's opioid problem has reached epidemic levels. The Substance Abuse and Mental Health Services Administration's (SAMHSA's) National Survey on Drug Use and Health estimated that some 23.5 million Americans are addicted to drugs and alcohol, with 17 million adult Americans are alcohol-dependent.
The opioid and alcohol addiction in the U.S. is costing taxpayers billions of dollars annually in healthcare cost. It is estimated that alcohol addiction in the U.S. alone total $30 billion annually while the estimated annual overall economic cost, reaches $235 billion.
The U.S. health care is spending at least $11 billion per year on illegal drugs while the aggregate yearly economic cost is believed to reach $193 billion, SAMHSA said.
A recent study by the National Council on Alcoholism and Drug Dependence Inc. (NCADD) has found that employers in the U.S. losses nearly $81 billion annually because of drug abuse. The NCADD data added that around 70 percent of the 14.8 million Americans suspected of using illegal drugs are working.
Sustained Release of Naltrexone, Holy Grail in Addiction Treatment
However, Granier believes that the current process of treating drug abusers, especially those addicted to opioids, is not as effective most of the time.
Granier pointed out that sustained release naltrexone products may become the gold standard of opioid addiction treatment in the future. Naltrexone is an antagonist that blocks certain receptors in the brain and prevents the euphoric effects caused by opioid use. "As long as you have therapeutic levels of naltrexone in your system, you can't get high," Granier boasts.
Naltrexone was developed in the 1960s and was approved by the Food and Drug Administration (FDA) to treat opioid addiction in 1984. The drug shows minimal sideeffects following detoxification and does not have any potential for abuse. It is also non-addictive. Sadly, Granier said virtually no one was promoting the drug as an effective drug addiction treatment option until recently
Currently, only Alkermes (ALKS), a $8.39 billion pharmaceutical company, is marketing naltrexone under its Vivitrol brand. But BioCorRx is in the preclinical stage of developing its own injectable naltrexone called BICX101..
BICX101 is being developed with the goal of sustained therapeutic release of naltrexone for one month, but using a delivery technology that would require much less volume and a smaller needle than Vivitrol. The company states that they are aiming for a product than can also be administered subcutaneously.
According to Granier, solving America's drug addiction problem also requires education, as well as cutting off the illegal drug supply. He mentioned organizations like Natural High, which according to their website, states that their mission is "to inspire and empower youth to find their natural high and develop the skills and courage to live life well."
BioCorRx Announces BICX101 Preclinical Update; ASAM Attendance
ANAHEIM, CA / ACCESSWIRE / April 5, 2017 / BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that is has received updated data from preclinical studies for BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The Company is pleased to announce that three different formulations were successful in reaching 28 days of sustained release of naltrexone. The Company also announced that it will have a booth in the exhibit hall at the American Society of Addiction Medicine (ASAM) conference in New Orleans this week. ASAM is the leading addiction medicine professional society in the U.S. representing over 4,300 physicians, clinicians and professionals with a focus on addiction and its treatment.
Brady Granier, CEO, President, and Director, stated, “We are thrilled that we have been able to hit this milestone in vivo for the first time. Thanks to the work of our team and the folks at TheraKine and Covance, we are getting closer to a final product. We still need to fine tune the formulation to maximize performance, but this data is very exciting. Not only have we reached 28 days of release, but we did it with an injection volume of only 1 ml.”
Granier added, “In terms of the Pre-IND meeting request with the FDA, we are working with Innovative Science Solutions to get that done as we are eager to meet with the agency. We anticipated the request being submitted this week and we are still working to that end. It could go into next week depending on what finishing touches are needed, if any, after all regulatory experts have had a chance to review and comment on the final application. We will also be at ASAM later this week which we are very excited about as this is one of the best events in the industry. We will be meeting many key opinion leaders and educating countless addiction specialists about our BioCorRx Recovery Program and BICX101. The attendees of ASAM are all potential partners or customers for our products and programs.”
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
0.20 got hit ;)
Time to break the 0.20 resistance !!
Email address ?
Funny how no one wants to touch the 0.20 :))))
0.20 + any second now !!
Been here for long time . Seen BICX trading up and down . Seen it triple in 2 days then fall back below starting PPS in 2 days too !!! But that is the 1st time I see steady Solid trading up !
Till 4/15/17
Same Good news on a different Site !! 4/3/17
http://www.opalesque.com/663871/Hedge_fund_Alpine_Creek_completes_equity_financing_of387.html
Private Equity Firm Alpine Creek Completes Equity Financing of Biotech BioCorRx
GuruFocus.com
April 02, 2017
- By Alyangka Francheska Manalo
Private equity firm Alpine Creek has completed its equity financing of BioCorRx Inc. (BICX), an addiction treatment company offering a unique approach to the treatment of substance abuse addiction.
The new round of funding will include the closing of nearly $5 million investment from strategic investor Alpine Creek Capital. Their initial investment of $2,500,000 received in June 2016 has allowed BioCorRx to reach major milestones and expand into the development of injectable naltrexone.
Lourdes Felix, CFO, COO and director, stated, "We appreciate the support we have received from investors, as this financing strengthens our balance sheet while allowing us to continue to execute on our business plan. Preclinical studies of BICX101, a new injectable naltrexone technology for the treatment of substance abuse addiction, have produced results consistent with our goals. This funding will allow us to accelerate our preclinical activities, and we remain on track to complete the current study already underway in the following weeks. Once the study is completed, we plan to request a pre-IND meeting with the FDA to present the data. In addition, this financing will allow us to accelerate sales and marketing activities related to our BioCorRX Recovery Program."
In June 2016, Alpine Creek committed to invest an initial $2,500,000 with an additional $2,500,000 to BioCorRx. Alpine Creek Capital Managing Partner Travis Mullen commented at that time, "We couldn't be more excited about our investment in BioCorRx and the cutting edge program they have in place. The BioCorRx Recovery Program which includes this naltrexone delivery system coupled with the tangible counseling program is literally saving lives and we look forward to arming as many families as possible with this amazing tool for their battle against alcohol or opioid addiction."
Brady Granier, CEO of BioCorRx, Inc., welcomed Alpine Creek's investment and said that the fund is the largest position made in BioCorRx in its more than five years of operations. He said, "Since last year, Alpine has been a valued and trusted financial partner of BioCorRx and this transaction is a testament to the hard work that has been done by everyone in our company to create a product that we believe has great potential to combat this opioid epidemic, as well as the much larger alcoholism problem destroying families across the world. Our program and service model has evolved over the years into something we believe is truly unique and effective in battling addiction. With this significant partnership with Alpine, we will be able to start taking advantage of initiatives we have been dreaming about for years. The folks at Alpine are not your average investors. They really care about what we are doing and the impact it can make and they are also rolling up their sleeves and getting in the trenches along-side us to beat addiction."
BioCorRx Signs Deal With Anaheim to Treat Opioid and Alcohol Addiction
Last month, BioCorRx finalized a deal with Anaheim Mayor Tom Tait to assist the city in in treating residents with opioid and alcohol addiction.
Under the agreement, BioCorRx will offer its BioCorRx Recovery Program to residents of Anaheim suffering from alcohol and opioid addiction as an expansion of the Drug Free Anaheim Program unveiled in 2016's State of the City address aimed at encouraging chronic drug users to seek assistance. The Drug Free Anaheim Program offers addicts the opportunity, through local police stations in Anaheim, Orange County's most populous city, to request help in exchange for free treatment.
The BioCorRx Recovery Program includes an implant compounded per patient use using the medication, naltrexone, combined with a structured, proprietary counseling program and peer support for a year. These specifically formulated, biodegradable pellets are typically inserted beneath the skin in the lower abdominal area. Naltrexone is a non-addictive opioid antagonist used for the treatment of alcohol and opioid dependence. It can reduce or eliminate cravings for alcohol and opioids as well as block dangerous effects of opioid use such as overdose as commonly seen in heroin use.
BioCorRx Gets OTCQB Upgrade
Last week, BioCorRx said that the company's shares have been approved for quotation on the OTCQB(R), and will continue to trade under the symbol BICX. Investors can find real-time quotes and market information for the company on www.otcmarkets.com.
Granier stated, "We are pleased to have been accepted for quotation on the OTCQB, which reinforces our commitment to the highest levels of transparency and corporate governance."
DISCLOSURE: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I have no business relationship with any company whose stock is mentioned in this article.
No one is selling anymore .. everyone owning BICX is convinced in the stock !
Yep any second now ... here we gooooooooooo!
NSAV Announces 10% Dividend To Shareholders
Font size: A | A | A
9:20 AM ET 3/31/17 | Marketwired
CRESCO, PA--(Marketwired - Mar 31, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a 10% dividend for the holders of its common stock. The dividend will be a share dividend and will be evenly distributed to the shareholders depending on their percentage of ownership in NSAV. This will ensure that there is no dilution to any NSAV shareholder. The Company will announce the record date and other details of the dividend in the coming weeks.
The Company also announced that its transfer agent has resumed communications with NSAV shareholders and has officially confirmed the Company's position that no dilution of NSAV shares has occurred following the public dispute of several weeks ago. The Company's president, James Tilton, has had friendly and productive discussions with the transfer agent over the past several days and all parties are committed working together in the best interest of all NSAV shareholders.
Further, although the Company's business model is growth by acquisition, the desire of NSAV is not to dilute its shareholders when making acquisitions. The Company's vision is to pay for its acquisitions out of the earnings of the companies it acquires.
The Company also announced a clarification of Tuesday's press release, as it has received numerous emails and telephone calls from shareholders. As previously announced, the January 29, 2016 agreement between NSAV and its former management and China Food and Beverage Company (OTC: CHIF) expired on June 30, 2016 and is now null and void. A copy of this agreement can be found in the Company's 8-K filed with the SEC on June 17, 2016. One of the clauses in the agreement is that KBM Worldwide have pledged to it, an additional reserve of 3.0 billion shares of its common stock in a settlement negotiated by the Company's previous management. The Company's current management believes that as this agreement is null and void, the clause pertaining to the additional reserve of its shares is also null and void. No other NSAV share issues were affected by this clause. As previously stated, the Company feels that this action is in the best interest of NSAV and its shareholders.
James Tilton, president of NSAV stated, "I am personally honored to have the privilege of announcing this dividend to our loyal shareholders. I believe our dividend is many times what even the major corporations distribute to their shareholders in terms of percentage. I will work tirelessly to ensure that all of our Company's shareholders can be rewarded with additional dividends like this in the future. That is my personal guaranty."
NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the medical cannabis industry, as well as other areas of the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services, patents and trademarks and information technology.
For further information please contact NSAV at 1 (570-595-2432) or jamestilton@netsavingslinkinc.com.
The NSAV Twitter account can be accessed at https://twitter.com/NSAV_MJTechCo
The NSAV Facebook account can be accessed at https://www.facebook.com/Net-Savings-Link-Inc-768628693317257/
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.
For further information please contact NSAV 1 (570-595-2432) jamestilton@netsavingslinkinc.com
Smart investors are loading up Big time !!! ONLY THE SMART ONES THOUGH :)
any News or updates from the public conference at Meetmax .?
PIP ..... Is that our "GEORGE O'NEIL" ???
https://www.lastingfix.com/?gclid=CLPsi9_b-9ICFQsQgQodSKEBow
Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. Provide Updates and Outlook in a New Audio Interview with SmallCapVoice.com
Mar 27, 2017 08:00:00 (ET)
Brady Granier, CEO, President, and Director and Lourdes Felix, CFO, COO and Director of BioCorRx Inc. Provide Updates and Outlook in a New Audio Interview with SmallCapVoice.com
AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (OTCQB:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/3-24-17-smallcapvoice-interview-with-biocorrx-inc-bicx.
Brady Granier and Lourdes Felix called in to SmallCapVoice.com, Inc. to go over the exciting recent news for the Company. BICX recently announced it moved up to the OTCQB, their upcoming presentation at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29(th) , the positive preliminary data from preclinical studies evaluating BICX101, the validating work BICX is doing with the City of Anaheim to treat opioid and alcohol addiction, and more.
"We are very happy with the way things are progressing with the company's initiatives," stated Granier. "This interview restates some of our most recent developments and we look forward to providing more updates in the future."
About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for their ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/.
About BioCorRx
BioCorRx Inc. (BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
NSAV ANNOUNCES 2.5 BILLION SHARE REDUCTION
NSAV ANNOUNCES 2.5 BILLION SHARE REDUCTION
Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved a 2.5 billion reduction of its authorized shares. The Company took this action after lengthy consultation with its attorneys, investment bankers and advisers, in order to ensure that the amount of the share reduction benefits all NSAV shareholders, while still allowing the Company to grow and make acquisitions. The Company wants to reassure all of its shareholders that no substantial dilution of its shares has taken place or will take place and that NSAV is not planning or even considering a reverse split of its shares.
The Company also announced that an additional 2.5 billion of its authorized shares have been placed on hold for possible cancellation. The Company wants to ensure that the amount of authorized shares will enable NSAV to fulfill its business plan and, in time, pay a substantial share dividend to its shareholders.
Further, although the Company's business model is growth by acquisition, the desire of NSAV is not to dilute its shareholders when making acquisitions. The Company's vision is to pay for its acquisitions out of the earnings of the companies it acquires.
The Company also announced the launch of its Twitter and Facebook accounts.
The NSAV Twitter account can be accessed at https://twitter.com/NSAV_MJTechCo
The NSAV Facebook account can be accessed at https://www.facebook.com/Net-Savings-Link-Inc-768628693317257/
James Tilton, president of NSAV stated, "I am truly pleased that I can finally confirm the long awaited dramatic reduction of the NSAV authorized shares. Once again, I can assure all of our shareholders that this action will benefit them. As I have stated on numerous occasions, I am fully committed to only taking actions that are in the best interest of all NSAV shareholders. I also want to reaffirm that I do not own a single share of NSAV common stock or any security that converts into even one share of common stock."
Mr. Tilton went on to state, "I sincerely hope that by placing a hold on an additional 2.5 billion authorized shares, it will ease the dilution fears of many of our shareholders. It has been my personal vision since I took over NSAV, to pay a dividend to our loyal shareholders, in order to show my deep appreciation for their continued support and confidence in me."
Mr. Tilton further went on to state, " I can't express in words how thrilled I am to personally announce the launch of our company Twitter and Facebook accounts. As most of you know, I stay up until the wee hours of the morning until I answer all of your emails. I truly hope that these social media accounts bring me even closer to our shareholders and enhance our communication. However, please don't stop sending me your thoughts by email, as I love the personal one to one interaction with our shareholders."
NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the medical cannabis industry, as well as other areas of the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, financial services, patents and trademarks and information technology.
For further information please contact NSAV at 1 (570-595-2432) or jamestilton@netsavingslinkinc.com .
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.
.0006s :)
Majority of US Employers: Prescription Drug Misuse Is Grounds for Termination
Workplace can play a key role in helping addicted employees
March 21, 2017 | About: BICX
A majority of American employers believe that prescription drug misuse in workplaces is a justifiable reason to terminate an employee, according to a survey by the National Safety Council (NSC).
The survey interviewed 501 companies across a geographically representative sample of U.S. employers with 50 or more employees. It found that a big 70% of employers admit feeling the direct impact of prescription drug abuses, and 71% of those polled consider prescription drug abuse a disease that needs to be treated.
"Employers must understand that the most dangerously misused drug today may be sitting in employees' medicine cabinets," said Deborah A.P. Hersman, president and CEO of the NSC. "Even when they are taken as prescribed, prescription drugs and opioids can impair workers and create hazards on the job. We hope these findings prompt employers to take the lead on this emerging issue so that workplaces can be as safe as possible."
Brady Granier, president, CEO and director of BioCorRx Inc. (BICX), agrees that this is a disease and added that there is a need for EAP programs to begin adopting medication-assisted treatment (MAT) programs that use naltrexone and outpatient therapy more rapidly. He feels that it’s not only an effective and efficient form of treatment for many but that it can allow one to be in recovery while productively working.
•Warning! GuruFocus has detected 5 Warning Signs with BICX. Click here to check it out.
•BICX 15-Year Financial Data
•The intrinsic value of BICX
•Peter Lynch Chart of BICX
Granier said there is a correlation between drug abuse and job status in the U.S. He added that drug abuse diminishes a person’s employment status because of lost productivity and declining work performance.
Employers lose $81 billion annually due to drug abuse
Data from the National Council on Alcoholism and Drug Dependence Inc. (NCADD) estimates drug abuse losses to employers reach $81 billion annually. According to the NCADD, 70% of the 14.8 million Americans suspected of using illegal drugs are working.
Indeed, over the past 10 years, the number of American workers abusing drugs has reached an all-time high. A workplace urine drug test conducted by Quest Diagnostics showed a 4% increase among 9.5 million urine drug tests in the U.S. workforce in 2015 compared to 3.9% in 2014. The tests also showed that cocaine, amphetamines and methamphetamines are the favored illicit drugs in the U.S. workforce.
And the number could go higher.
The American Association of Occupational Health Nurses (AAOHN) and the American College of Occupational and Environmental Medicine (ACOEM) added that the U.S. workplace must prepare itself for the possible impacts of the changing acceptance toward marijuana and its medicinal and recreational purposes as well as new state laws decriminalizing its use.
Pam Carter, R.N. and president of AAOHN, commented on the trend: “Twenty states and the District of Columbia have enacted laws to legalize medical marijuana and two states have approved its recreational use by adults. With growing advocacy, other states seem ready to follow. Mainly because of such rapid change, both of our associations believe it is time to address workplace health and safety concerns when workers have impaired functioning from this and other drugs.”
Employees caught selling drugs in the workplace
More alarming than lost productivity and tardiness is the admission of at least 14% of the employers polled by the NSC that they caught an employee selling drugs in the workplace. Other findings cited the following issues because of prescription drug use: 39% said workers have been caught taking drugs while on the clock; 39% said absenteeism; 32% said a positive drug test indicated use; 29% said a worker had been found to be impaired or showed decreased work output; 29% said a family member complained; 22% said another employee complained to human resources; and15% said an injury or near-miss occurred.
The NCADD added these problem areas caused by prescription drug use: After-effects of substance use (hangover, withdrawal) affecting job performance; poor decision making; loss of efficiency; theft; lower morale of co-workers; increased likelihood of having trouble with co-workers/supervisors or tasks; preoccupation with obtaining and using substances while at work, interfering with attention and concentration; illegal activities at work including selling illicit drugs to other employees; higher turnover; training of new employees; and disciplinary procedures.
What employers can do
The workplace can play a crucial role in addressing drug dependency, according to NCADD. Employers can establish programs such as an Employee Assistance Program (EAP) and promote a drug-free workplace program (DFWP). Employers can also provide additional incentives by encouraging their families to refer a suspected drug addict to community resources and services.
Many individuals and families face a host of difficulties closely associated with problem drinking and drug use and bring these problems into the workplace directly or indirectly. By encouraging and supporting treatment, employers can dramatically assist in reducing the negative impact of alcoholism and addiction in the workplace.
The NSC also recommends that employers put strong policies in place against prescription drug misuse while expanding drug testing panels to include opioids. Training supervisors and employees on how to spot signs of misuse is also a positive step. It is also best to treat substance use problems as a disease and leverage employee assistance programs to help employees return to work.
Disclosure: I have no positions in any stocks mentioned and no plans to initiate any positions within the next 72 hours. I have no business relationship with any company whose stock is mentioned in this article.
Start a free seven-day trial of Premium Membership to GuruFocus.
BioCorRx Announces Upgrade to the OTCQB(R)
ANAHEIM, CA / ACCESSWIRE / March 22, 2017 / BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, is pleased to announce that the Company’s shares have been approved for quotation on the OTCQB®, and will continue to trade under the symbol BICX. Investors can find real-time quotes and market information for the company on www.otcmarkets.com.
Brady Granier, CEO, President, and Director stated, “We are pleased to have been accepted for quotation on the OTCQB, which reinforces our commitment to the highest levels of transparency and corporate governance.”
About OTCQB®
The OTCQB® Venture Market, operated by OTC Markets Group Inc., requires companies to remain current and compliant in their reporting, and undergo an annual verification and management certification process. These standards provide improved investor confidence through verified information, as well as greater information availability, and transparent prices for investors with Real Time Level 2 quotes.
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
SOURCE: BioCorRx Inc.
IMO , today's news shows that BICX management is legit and serious about executing their plans in a timely manner !
GOOOOO BICX
BioCorRx Announces Updates on Preclinical Studies of BICX101 and Pre-IND Meeting Request with FDA
ANAHEIM, CA / ACCESSWIRE / March 21, 2017 / BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced positive preliminary data from preclinical studies evaluating BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. Thus far in the preclinical studies, the product is successfully delivering above adequate sustained release levels of naltrexone. The study has so far confirmed a number of the expected advantages of BICX101. The Company is also expecting Innovative Science Solutions (ISS) to finalize and submit the Pre-IND meeting request application in the first week of April.
Brady Granier, CEO, President, and Director, stated, "This third round of in vivo studies has produced some very exciting results thus far. We still have a couple more weeks or so before this study is completed and the final report from Covance is delivered. What is particularly exciting about this round of data is that we have discovered that we may have two different lead formulations that may lead to 2-3 different types of products in the future. Our primary goal is to achieve a once a month injectable product in a low volume and small needle, along with many other advantages over current products, but what we discovered in the last few weeks of studies may lend itself to another possible product. We have also discovered that we can deliver two weeks of drug release in vivo in a very low volume of approximately 0.5 ml. This could lead to the possibility of a self-administered, at-home product. The implications of this can be very profound in terms of how alcohol abuse and opioid overdose protocols are amended in the future. Alcohol Use Disorder (AUD) is a much larger problem than alcohol addiction, as many abuse alcohol without necessarily being addicted. A product such as this might be used for harm reduction for those who have an alcohol use problem, but not yet full-blown addiction. In terms of opioid overdose reversal using naloxone, there could be an opportunity for a product to be administered after naloxone, which can add further protection to that individual by extending overdose protection by a couple of weeks. Of course, more investigation will need to take place for these indications, but the feedback from addiction experts on these is very positive. With regard to our main objective of the monthly injectable, we have identified at least two formulations that are releasing the drug quite nicely in vivo and we are anticipating more data points in the very short term."
"We are also working with ISS to finalize the Pre-IND meeting request, as we feel confident that we have enough data to have a meeting with the FDA. We expect to have additional data by the time the actual meeting occurs. Once the meeting is requested, it can typically take 60 days for the actual meeting to take place, but that is not controlled by us. More updates on additional results of the preclinical studies, as well as the Pre-IND meeting, are anticipated in the coming weeks."
About BioCorRx
BioCorRx Inc. (OTC PINK: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Companies Aiming for the Billion-Dollar Opioid Addiction Market
March 18, 2017
- By Alyangka Francheska Manalo
The global opioid market reached $33.924 billion in 2014 and is estimated to have reached $34.89 billion in 2015, data from Persistent Market Research shows. Experts believe the market will reach $42.16 billion by 2021, or a 3.2% compound annual growth rate (CAGR).
The steady rise in the opioid market is being attributed to prescription pain medication and the ease in getting illegal opiate-based drugs. It is estimated at least 9% of the population has misused opioids at one point in their life.
•Warning! GuruFocus has detected 3 Warning Signs with INSY. Click here to check it out.
•INSY 15-Year Financial Data
•The intrinsic value of INSY
•Peter Lynch Chart of INSY
Health care workers are also pointing to increased palliative care facilities, revisions in rules for prescription of opioids and widespread focus of generic manufacturers towards Abuse-Deterrent Formulations (ADF) as catalysts for pushing the opioids market up in North America and Europe. The Asia Pacific market is projected to post the highest CAGR of opioids from 2015 to 2021, followed by North America. The increase in health care expenditure in the Asia Pacific market, coupled with the rising attention toward palliative care, is promoting the growth of opioids in the region.
Rise in opioid prescriptions causing addiction
North America is the largest opioid market. Data from GBI Research shows the U.S. accounts for nearly 70% of the world's opioid market, from $11 billion in 2014 to $17.7 billion by 2021.
The aging population in the U.S., rising cases of obesity, cancer, arthritis, diabetes and growing incidences of chronic pain are leading causes for the surge in the opioid market.
However, the analgesic nature of opioids makes it addictive to its users. An estimated 80% of the world's legal and illegal opioids are sold in the U.S. Researchers at Persistent Market said opioids are the most widely abused class of prescription drugs in the country and predict the unrestrained prescription and development of opioid tolerance toward codeine and morphine will further increase the demand up to 2021.
Deekshita Allavarapu, an analyst at GBI Research, said, "The FDA has raised concerns over the high use, and the potential for misuse, of opioids. This could lead to the enforcement of regulatory checks that affect the opioid treatment market and its potential growth. The result of these possible market restrictions, however, is that opportunities may open up for the development of abuse-deterrent opioids and of products that treat or prevent overdoses."
Pharmaceutical companies respond with more drugs
America's dependence on opioid prescription drugs has reached crisis levels. An estimated 3.5 million Americans, age 12 or older, are believed to be addicted to drugs and alcohol, according to the Substance Abuse and Mental Health Services Administration's (SAMHSA's) National Survey on Drug Use and Health. Interestingly, the pharmaceutical industry's response to this drug addiction crisis is more drugs. The abuse and misuse of opioids has resulted in a $1.4 billion opioid addiction treatment industry in the U.S. as of 2014, according to the Addiction Treatment Advisory Group's (ATAG) report, "The Role of Managed Care Pharmacy in Improving Access to Naloxone." ATAG was established by the Academy of Managed Care Pharmacy (AMCP) in 2015.
This billion-dollar opioid addiction management industry has prompted pharmaceutical companies, including Insys Therapeutics Inc. (INSY), Pfizer Inc. (PFE), Amphastar Pharmaceuticals Inc. (AMPH), Mylan N.V. (MYL), Opiant Technologies Inc. (OPNT), Adapt Pharma Ltd., Kaleo Pharmaceuticals, Alkermes (NASDAQ:ALKS) and newcomer BioCorRx Inc. (BICX), to offer their respective unique approaches to this market.
Anti-opioid addiction stocks
There are three leading opioid addiction treatment drugs currently available on the market. Suboxone, a combination of buprenorphine and naloxone, is being promoted and financed by the U.S. government as a safer alternative to methadone. Naltrexone is a pure opioid antagonist that has proven to be effective in reducing or completely reversing and blocking the effects of intravenously administered opioids. Then there is naloxone, a generic drug approved by the Food and Drug Administration (FDA), which is sold over the counter and without a prescription in some states for the reversal of opioid overdose.
Naltrexone - Alkermes and BioCorRx
Naltrexone is sold in the market under the brand name Vivitrol, which is manufactured by Alkermes. The company is selling Vivitrol at $1,300 per shot and promoting the drug as effective in blocking the effects of opioids. In the first three quarters of 2016, Vivitrol generated $55.8 million in sales for Alkermes. The company is hoping the drug will contribute between $700 million and $800 million in sales by 2018. Oral naltrexone is also available under the name Revia.
BioCorRx has partnered with TheraKine Ltd. in the development of its naltrexone injectable product, BICX101. They also have one or more other naltrexone formularies for use in an implantable form, which lasts several months. BICX101 is currently in preclinical development under BioCorRx Pharmaceuticals, a subsidiary or BioCorRx Inc. Brady Granier, president, CEO and director of BioCorRx, said BICX101 is being developed with the goal of improving patient compliance by reducing dose volume, needle size and many other factors which can make compliance with other products more challenging.
Granier said, "BICX101 is being developed with the goal of changing how addiction treatment will be managed in the future. Much like other chronic diseases, addiction should be managed long term and new products are needed to make that long-term treatment more efficient and accessible. We believe that BICX101 will be a product that can one day be used at home by patients or their caregivers."
Buprenorphine - Reckitt Benckiser
British multinational consumer goods company Reckitt Benckiser Group's (RB) Suboxone is currently dominating the opioid addiction market. Suboxone is intended as a maintenance treatment for opioid addiction. The drug comes in tablet form, however, making it more susceptible to abuse. There are even reports of accidental ingestion by children.
The Substance Abuse and Mental Health Services Administration's (SAMHSA) also expressed concern over buprenorphine since the drug itself is an opioid and can trigger dependency and the same euphoria when taking prescription drugs like acetaminophen/oxycodone (Percocet) or oxycodone (OxyContin).
Adding to the concerns is the case of 20-year-old Miles Malone, who died in 2010 after overdosing on Suboxone.
"I didn't know you could overdose on Suboxone," Shawn Verrill of South Berwick, Maine and a friend of Malone said in an interview at a federal prison in Otisville, New York. "We were just a bunch of friends getting high and hanging out, doing what 20-year-olds do. Then we went to sleep, and Miles never woke up."
Reckitt Benckiser is also at the center of a massive antitrust lawsuit after 35 states and the District of Columbia accused the company of using a series of "deceptive and unconscionable" practices to profit from drug addiction treatment when it spun off Indivior and a third company called MonoSol RX. Reckitt Benckiser is accused of "product hopping" for allegedly making minor tweaks to a product without actual development to apply for a new patent so it could keep its market share on Suboxone.
Naloxone - Adapt Pharma, Opiant Pharmaceuticals, Pfizer, Amphastar Pharmaceuticals, Kaleo
Approved by the FDA in 1971, naloxone is a first responder drug. It is often administered to patients suspected of opioid overdose, but its effect is limited and therefore not intended as a long-term opioid dependency treatment.
Adapt Pharma Ltd. is marketing the NARCAN Nasal Spray formulation. Adapt partnered with Opiant Pharmaceuticals (formerly Lightlake Therapeutics) to develop the NARCAN Nasal Spray using Opiant's intranasal opioid antagonist platform technology through a licensing deal. Two other companies, Hospira (a subsidiary of Pfizer) and Amphastar Pharmaceuticals, are also pioneers in injectable naloxone. The two companies, however, are being blamed for the sudden jump in the price of naloxone. Virginia-based Kaleo is marketing a naloxone auto-injector under the Evzio brand name. Evzio was priced at $690 for two packages in 2014. It is now $4,500, more than a 500% increase in just over two years.
Biotech giant Mylan was granted FDA approval to sell a naloxone injectable in 2014, while struggling company INSYS Therapeutics is hoping to revive its stock price after getting a naloxone candidate assigned as fast track eligible.
Conclusion
Naltrexone is the most promising of the three opioid addiction treatments for two reasons. It is a non-opioid that cannot be abused and it can prevent relapse and overdose.
There is no doubt the opioid addiction treatment market will continue to rise, not only in the U.S. but across the globe as well, due to the rise in opioid prescriptions. Aside from opioid addiction treatment, opioid pain management has also spawned other billion-dollar industries, including overdose and side effects such as constipation. Financial experts believe that if opioid addiction is wiped out, it would also take away billions of dollars of potential income from opioid submarkets - addiction, overdose and side effects.
"I see naltrexone one day becoming the gold standard for long-term addiction treatment," Granier said. "It's not only effective for opioid addiction, but it works very well for alcoholism in terms of craving reduction. You can't say that for the other most commonly used medications administered in medication-assisted treatment of addiction."
220K buy !!!